Here's your US product review news for week, in brief: The regulatory nightmare for Apricus Biosciences Inc.'s Vitaros (alprostadil, DDAIP.HCl) is continuing, as it reeled in a complete response letter nearly 10 years after it first received a "not approvable letter" from the US FDA.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?